RIGEL PHARMACEUTICALS INC (18)
Browse by Contract Category
Contracts
-
Rigel Pharmaceuticals, Inc. 2000 Employee Stock Purchase Plan, as amended
(Filed With SEC on August 3, 2021)
-
Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended
(Filed With SEC on August 3, 2021)
-
License and Collaboration Agreement by and between the Company and Eli Lilly and Company, dated February 28, 2021
(Filed With SEC on May 5, 2021)
-
Offer Letter from Rigel Pharmaceuticals, Inc. to David Santos, dated July 13, 2020
(Filed With SEC on November 5, 2020)
-
Exclusive Commercialization License Agreement between Rigel and Grifols Worldwide Operations Limited, dated January 22, 2019
(Filed With SEC on May 7, 2019)
-
Non-employee Directors Compensation Policy
(Filed With SEC on May 5, 2021)
-
2021 Cash Incentive Plan
(Filed With SEC on February 3, 2021)
-
Rigel Pharmaceuticals, Inc. 2018 Equity Incentive Plan, as amended
(Filed With SEC on August 4, 2020)
-
Open Market Sale AgreementSM, dated August 4, 2020, by and between Rigel Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on August 4, 2020)
-
Executive Severance Plan as amended
(Filed With SEC on May 5, 2020)
-
Offer Letter from Rigel Pharmaceuticals, Inc. to Wolfgang Dummer, dated October 3, 2019
(Filed With SEC on February 27, 2020)
-
Description of Capital Stock
(Filed With SEC on February 27, 2020)
-
2020 Cash Incentive Plan
(Filed With SEC on November 22, 2019)
-
Credit and Security Agreement, dated as of September 27, 2019, by and between the Registrant and MidCap Financial Trust
(Filed With SEC on November 5, 2019)
-
2018 Equity Incentive Plan, as amended
(Filed With SEC on August 6, 2019)
-
Collaboration and License Agreements with Kissei Pharmaceutical Co., Ltd
(Filed With SEC on February 28, 2019)
-
Supply Agreements with Kissei Pharmaceutical Co., Ltd
(Filed With SEC on February 28, 2019)
-
2019 Cash Incentive Plan
(Filed With SEC on February 1, 2019)
